Atria Wealth Solutions Inc. Acquires 1,205 Shares of Sanofi (NASDAQ:SNY)

Atria Wealth Solutions Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,370 shares of the company’s stock after buying an additional 1,205 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Sanofi were worth $814,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SNY. Envestnet Asset Management Inc. increased its position in Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after buying an additional 651,756 shares in the last quarter. Natixis Advisors L.P. increased its holdings in shares of Sanofi by 15.9% in the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock worth $135,618,000 after buying an additional 346,563 shares during the last quarter. Morgan Stanley increased its stake in Sanofi by 4.6% during the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after acquiring an additional 323,968 shares during the last quarter. Clough Capital Partners L P bought a new position in shares of Sanofi during the 3rd quarter valued at approximately $14,719,000. Finally, Soros Fund Management LLC bought a new stake in shares of Sanofi in the 3rd quarter worth about $11,533,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SNY shares. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Sanofi Trading Down 0.9 %

SNY opened at $49.01 on Friday. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.93. The company has a market capitalization of $123.98 billion, a P/E ratio of 24.63, a PEG ratio of 1.38 and a beta of 0.61. The stock’s fifty day moving average is $47.89 and its two-hundred day moving average is $48.27. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Analysts forecast that Sanofi will post 4.12 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is currently 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.